Esperion Therapeutics (NasdaqGM:ESPR) M&A announcement March 03, 2026 08:00 AM ET Company ParticipantsBen Halladay - CFOBetty Jean Swartz - Chief Business OfficerDan Bloomfield - Chief Medical OfficerJohn Harlow - Chief Commercial OfficerSerge Belanger - Managing Director in BioPharma Equity ResearchSheldon Koenig - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystDennis Ding - Vice President and Equity Research AnalystJoseph Pantginis - Managing Dir ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares are down during Tuesday’s premarket session as the company announced a definitive agreement to acquire Corstasis Therapeutics.This news comes as broader markets experienced declines, with major indices like the S&P 500 and Nasdaq both closing lower on the previous trading day.Esperion has entered into an agreement to acquire Corstasis, which developed Enbumyst, the first FDA-approved nasal spray diuretic for treating edema associated with congestive heart fai ...